Empagliflozin Reduces Risk for Progression in CKD

Empagliflozin is tied to a lower risk for kidney disease progression or death from cardiovascular causes vs. placebo in patients with chronic kidney disease at risk for progression. Among 6,609 patients, progression occurred in 13.1% and 16.9% with empagliflozin and placebo, respectively.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ